Vivinox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vivinox

Vivinox is a synthetic, pharmacy-only medicine containing the active compound Diphenhydramine hydrochloride, utilized for the short-term, symptomatic management of sleep disturbances. It is primarily classified as a first-generation H1-antihistamine that uses its inherent sedative-hypnotic properties to induce calmness and facilitate the onset of sleep. The product is frequently associated with German manufacturer Dr. Gerhard Mann Chem.-pharm.Fabrik GmbH.


Property Description
Active ingredient Diphenhydramine hydrochloride
Form Coated tablet (Dragee), Oral dosage form
Pharmacological class First-generation H1-antihistamine; Sedative-hypnotic
Common use Temporary sleep disturbances (Insomnia)
Origin Synthetic compound

What Type of Medicine is Vivinox and What is its Purpose?

Vivinox is officially recognized as a first-generation H1-antihistamine, a classification that is clinically recognized for its capacity to act as a CNS depressant by virtue of its chemical structure. Its general purpose is to aid patients experiencing acute, temporary difficulties with sleep initiation. The core mechanism is rooted in the targeted blockade of histamine receptors (H1) in the brain, interfering with histamine's role in promoting alertness. This specific compound is often preferred over modern second-generation antihistamines precisely because of this pronounced effect. This action generates a necessary state of calm and sedation, allowing an individual to more easily achieve sleep during periods of stress-related insomnia.

Composition and Physical Form of the Preparation

The drug is a mono preparation, signifying that it contains only the single active ingredient, Diphenhydramine hydrochloride. Vivinox is typically delivered as an oral dosage form, specifically a coated tablet (dragee). The coated tablet form is a defining physical feature, designed for ease of swallowing. The formulation uses pharmaceutically necessary excipients such as lactose and microcrystalline cellulose to form the solid base, ensuring stable and reliable oral administration of the active substance.

Regulatory References

  1. Diphenhydramine: MedlinePlus Drug Information

What side effects are possible with Vivinox?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of Vivinox (Diphenhydramine hydrochloride) based strictly on regulatory prescribing information from government authorities.

Documented Adverse Reactions

The most frequent adverse reactions reported in regulatory documentation relate to the central nervous system and its anticholinergic properties. These effects include sedation, sleepiness, dizziness, and disturbed coordination. Other frequently documented effects are dryness of the mouth, nose, and throat, as well as fatigue and epigastric distress.

Adverse effects are documented across various System-Organ Classes, including:

System-Organ Class Examples of Documented Effects
Nervous System Sedation, dizziness, confusion, tremor, blurred vision
Gastrointestinal System Nausea, vomiting, constipation, diarrhea
Cardiovascular System Hypotension (low blood pressure), tachycardia (fast heart rate), palpitations

Serious Adverse Reactions and Safety Constraints

Official labeling records clinically significant adverse reactions, though rare, such as convulsions (seizures), anaphylactic shock, and severe blood disorders, including agranulocytosis and hemolytic anemia.

The regulatory profile mandates caution due to the drug's action, advising against use in individuals with pre-existing conditions such as narrow-angle glaucoma, symptomatic prostatic hypertrophy, or bladder-neck obstruction.

Population-Specific Safety Notes

Explicit safety statements apply to specific groups. The medicine is contraindicated in neonates, premature infants, and nursing mothers. Regulatory information highlights that elderly patients are more susceptible to adverse effects like dizziness, sedation, and hypotension. Furthermore, pediatric patients may experience a paradoxical effect, such as excitation.

Overdose and Emergency Response

A Vivinox overdose (Diphenhydramine hydrochloride) is characterized by severe and potentially life-threatening effects on the central nervous, cardiovascular, and autonomic nervous systems. Documented clinical manifestations can include a spectrum of CNS effects, ranging from profound drowsiness and sedation to agitation, delirium, and hallucinations. Severe toxicity often presents with marked anticholinergic signs such as dilated pupils (mydriasis), dry mouth, urinary retention, and significant tachycardia.

Immediate medical assistance is required for any suspected overdose due to the potential for severe complications. Official regulatory documents indicate that severe toxicity can rapidly lead to life-threatening outcomes, including generalized convulsions, cardiac arrhythmias, circulatory collapse, and respiratory failure. In such instances, emergency services must be contacted without delay, and immediate transportation to a hospital is necessary.

Overdose management is symptomatic and supportive, as no specific antidote is known. Hospital monitoring is often required, particularly continuous cardiac monitoring, due to the critical risk of arrhythmias. Regulatory labeling notes that children may be more susceptible to CNS excitation, while elderly patients may experience more pronounced confusion and anticholinergic effects.

Therapeutic Uses of Vivinox

Vivinox (Diphenhydramine hydrochloride) is commonly used across therapeutic domains involving certain distressing symptoms, generally applied exclusively for the symptomatic management of temporary sleep difficulties in adults.

The medication is relevant for addressing symptom clusters that interfere with daily comfort and prevent individuals from achieving necessary rest during short-lived episodes. It is primarily used for short-term insomnia, transient sleep disturbances, and acute episodes involving difficulty falling asleep and pre-sleep inner tension or restlessness. Its role in symptomatic relief is often described as:

“The benefit provided supports a state of relaxation that contributes to assisting with the transition to sleep.”

In clinical scenarios, the product is commonly used across conditions presenting with transient or acute symptom patterns, such as sleeplessness triggered by situational factors. This includes real-world scenarios like temporary disturbances due to stress-related anxiety or sleep disruption associated with jet lag or shift work. By addressing these symptoms, it offers supportive therapeutic benefit that helps ease the overall symptom load and contributes to improved day-to-day comfort during periods of heightened symptoms.


Quick Fact: Relief for Difficulty Falling Asleep
Symptomatic Focus: Relief for sleep onset latency and pre-sleep agitation in adults.

Eligibility and Restrictions for Use

Official Eligibility Profile for Vivinox (Diphenhydramine hydrochloride)

The eligibility for Vivinox is defined by official regulatory documents, establishing who is permitted to use the medicine and who is formally excluded.

Vivinox is primarily established for use in Adults for the short-term, symptomatic management of sleep disturbances. Use is not recommended in children and adolescents under 16 years of age.


Populations for Whom Use is Contraindicated

Official labeling states that Vivinox is contraindicated and must not be used in several patient groups, including:

  • Nursing Mothers (breastfeeding women) and Neonates or Premature Infants.
  • Patients with Hypersensitivity to the active substance or related antihistamines.
  • Individuals currently taking Monoamine Oxidase Inhibitors (MAOIs) or within two weeks of stopping them.
  • Patients with closed-angle glaucoma, stenosing peptic ulcer, or pyloroduodenal obstruction.

Conditions Requiring Caution or Restriction

Use requires caution in patients with specific underlying conditions. This includes individuals with moderate to severe hepatic or renal impairment (liver or kidney issues), a history of epilepsy or seizure disorders, or certain respiratory illnesses like Chronic Obstructive Pulmonary Disease (COPD). Older adults (60 years) should also use the medicine with caution due to increased risk of side effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Vivinox are officially documented and primarily result from additive pharmacological effects or changes in metabolism.

Documented Interaction Categories

The following categories of products and substances have known interactions based on regulatory labeling:

  • Central Nervous System (CNS) Depressants: Co-administration with other depressants, such as hypnotics, sedatives, tranquillisers, or narcotic analgesics, leads to an enhanced additive CNS depressant effect. Alcohol must be avoided due to the potentiation of these effects.
  • Monoamine Oxidase Inhibitors (MAOIs): Combining with MAOIs is explicitly restricted. MAOIs inhibit the breakdown of the active substance, leading to increased exposure. A two-week avoidance period after stopping MAOI treatment is required before using this medicine.
  • Anticholinergic Drugs: Co-use with medicines such as tricyclic antidepressants, certain antiparkinsonian agents, or atropine can lead to the potentiation of anticholinergic side effects.
  • Antihypertensives: Caution is required as the drug may potentiate the hypotensive (blood pressure-lowering) effects of these medicines.
  • Other Antihistamines: Preparations containing the active substance or similar antihistamines should not be combined with this product.

These restrictions establish that co-administration with MAOIs, alcohol, or other diphenhydramine-containing products is contraindicated, while co-use with other CNS depressants, anticholinergics, or antihypertensives requires caution to manage documented changes in effects.

Mechanism of Action

Vivinox, containing diphenhydramine, functions as a first-generation H1-histamine receptor antagonist. The molecule traverses the blood-brain barrier, exhibiting targeted activity primarily within the central nervous system. Its primary biological target is the histamine H1 receptor, where it competitively binds to and blocks the receptor, preventing the endogenous agonist histamine from initiating signal transduction. This interaction inhibits the G-protein-coupled signaling cascade typically downstream of H1 receptor activation.

Simultaneously, diphenhydramine acts as a non-selective antagonist at peripheral and central muscarinic acetylcholine receptors (M1-M5). Binding to these receptors blocks cholinergic transmission. The system-level physiological consequence of both the H1 receptor antagonism and the muscarinic receptor antagonism is a generalized reduction in neuronal excitability and central nervous system activity, leading to modulation of the sleep-wake cycle and altered motor output.

Dosage and Administration Information

How to Use Vivinox: Administration Guidelines

Vivinox (Diphenhydramine hydrochloride 50 mg coated tablet) is intended for the standard, short-term management of temporary sleep difficulties.


Standard Dosing and Frequency

Instruction Category Guideline
Route of Administration Oral administration only.
Adult Dose The standard single dose is 50 mg (one tablet) at bedtime.
Maximum Dose Do not exceed 50 mg or one dose in any 24-hour period.
Frequency Once daily, as needed for temporary sleeplessness.

Administration Timing and Course Duration

The tablet should be taken 20 to 30 minutes before going to bed to ensure its effect aligns with the intended time of sleep. It may be administered with or without food. The tablet must be swallowed whole with water and should not be chewed.

Vivinox is strictly for short-term use. The medication should not be used continuously for longer than 7 to 14 days without medical advice, as it is intended only for transient symptoms.

Population-Specific Rules

For specific populations, caution and dose adjustments are necessary:

  • Older Adults: A lower initial dose may be advisable due to increased sensitivity.
  • Hepatic/Renal Impairment: A lower dose might be required in patients with moderate to severe kidney or liver impairment.
  • Children and Adolescents: The 50 mg sleep aid formulation is not for use in children under 12 years or under 18 years, depending on regional standards.

These administration guidelines define a standardized, time-critical protocol for the use of the product, ensuring the single daily dose is limited in both amount and duration.

Recent Clinical Evidence

Research evidence / Overview of studies for Vivinox


Evidence for Use in Temporary or Occasional Sleeplessness

The primary evidence base for research on Vivinox's use for temporary or occasional sleeplessness comes from Randomized Controlled Trials (RCTs). These trials constitute the primary type of research and were used in studies exploring how symptoms change over short time intervals. Researchers conducted these trials, often against an inactive substance (placebo), to see how the compound was observed under specific, controlled conditions. The studies primarily monitored sleep onset latency (the time measured for an individual to fall asleep). They also observed outcomes reflecting total sleep time and the patient-reported experience of sleep quality. The study populations were mainly adults experiencing acute or episodic changes in their sleep patterns.

Studies conducted during periods of increased symptom activity reported a difference in measurements of sleep onset latency when comparing observed populations to placebo groups. Findings describe patterns observed in the studies concerning short-term use. This evidence contributes to understanding symptom patterns observed during studies examining patient-reported experiences related to temporary sleep difficulties.


Long-Term Study Data and Duration of Observation

The research for Vivinox has primarily focused on its use for short-term or episodic symptom patterns. The majority of the foundational studies and systematic reviews concentrate on single-dose effects or treatment periods lasting up to two weeks, which is the definition often used for occasional or temporary sleeplessness.

Evidence derived from settings with varying symptom burdens show that follow-up durations were limited in most of the available research. Therefore, long-term effects are not fully established. There is limited information for long-term outcomes, meaning that the research does not provide significant insight into the effect of continuous use of the medicine on sleep patterns or daily functioning for longer periods. The available data show patterns related to temporary conditions, but research exploring extended symptom changes is lacking.


Evidence in Special Populations

Research examining temporary conditions was conducted mainly in the general adult population (under 65 years of age). However, the evidence is limited regarding specific groups. For example, there is limited information on how the medicine was observed in Older Adults (age 65 and above). Data for certain groups remain insufficient, and for this reason, specific research focusing on older adults is a documented evidence gap. Similarly, while some evidence exists concerning adolescents, specific, dedicated studies focusing only on this age group are not as common as those for younger adults.


Consistency of Evidence and Key Limitations

Scientific reviews of the available data consistently find that the evidence base, while recognized by regulators, often comprises trials of varying ages and methodologies. A significant research limitation is the age of some key data. Another key limitation is that sample sizes were modest in some older studies. Research exploring short-term symptom changes was associated with limited data on residual sedation or psychomotor performance the morning after administration, leaving a degree of uncertainty regarding psychomotor or cognitive performance the following day.

Key Studies & References

  1. Diphenhydramine in insomniac family practice patients: a double-blind study
  2. Sleep aids: Understand options sold without a prescription (Includes discussion of limited long-term data and risks in older adults)
  3. Diphenhydramine (e.g., Benadryl) - Evidence for Cognitive Safety in Older Adults and Dementia Risk

Frequently Asked Questions (FAQ)

Common questions about Vivinox (FAQ)


Q: How quickly is Vivinox supposed to start working?

Studies and official information indicate that it is normally expected to begin working within about mathbf30 minutes after it is taken. The maximum effect is typically achieved in approximately one hour. This timing aligns with the instruction to take it shortly before going to bed.


Q: Is it necessary to avoid alcohol completely while taking Vivinox?

Regulatory documents state that alcohol mathbfmust be avoided while using this medicine. This is because alcohol has an additive effect, leading to a risk of enhanced central nervous system depressant effects, which can increase drowsiness and impair coordination.


Q: Does the food you eat affect how Vivinox works?

Official administration guidelines state the medicine may be taken mathbfwith or without food. Taking it with food is described in some documents as a way to potentially manage minor stomach upset.


Q: What happens if you stop taking Vivinox suddenly?

This medicine is intended strictly for mathbfshort-term use, as defined by official documents (maximum 7 to 14 days). Some users who have used it for extended periods may experience a temporary return of difficulty sleeping upon discontinuation. This effect is sometimes referred to as mathbfrebound insomnia.


Q: Can Vivinox cause headaches or dizziness?

Regulatory documentation lists mathbfdizziness as a common adverse reaction related to the drug’s effects on the central nervous system. mathbfHeadache is also documented as a possible side effect, though it is reported less frequently than effects like drowsiness or dry mouth.


Q: Is Vivinox known to be addictive?

The active ingredient in Vivinox is mathbfnot classified as a controlled substance under federal schedules. However, official documents restrict its use to a short duration (maximum 7-14 days) to minimize potential risks associated with tolerance and dependency.


Q: Is Vivinox considered a controlled substance?

The active ingredient in this medicine, diphenhydramine hydrochloride, is mathbfnot listed as a controlled substance under federal or international drug schedules. In many jurisdictions, it is classified as an over-the-counter or pharmacy-only medicine.


Q: Does Vivinox have any known severe allergic reaction risks?

Official labeling records mathbfanaphylactic shock as a clinically significant, though rare, adverse reaction. Hypersensitivity (an allergy) to the active substance or related antihistamines is also a documented reason why the medicine mathbfmust not be used.


Q: What is the difference between Vivinox and other over-the-counter options for the same condition?

Official classification describes Vivinox as a mathbffirst-generation H1-antihistamine known for its sedative properties. Other non-prescription medicines for temporary sleeplessness may belong to mathbfdifferent pharmacological classes or may be second-generation antihistamines which do not share the same sedative properties.


Q: Can Vivinox cause changes in mood or sleep patterns?

Official records of adverse reactions include nervous system effects such as mathbfconfusion, mathbfrestlessness, and mathbfexcitation (particularly in pediatric patients). These effects represent documented, though not always common, changes in mental state and behavior.


Q: Are there different strengths or formulations of Vivinox available?

The Vivinox product is commonly available as a mathbf50 mg coated tablet for its labeled sleep purpose. The active ingredient, diphenhydramine, is available in other strengths and forms (such as liquids or injections) for other approved medical uses, typically under different product names.


Q: What should I do if I think I missed a dose of Vivinox?

Regulatory guidance suggests that a missed dose mathbfbe taken as soon as possible unless it is nearly time for the next scheduled dose. Due to the once-daily use, the instructions advise against doubling the dose.


Q: Is there a generic version of Vivinox available?

Vivinox is a brand name for a medicine containing the active ingredient mathbfdiphenhydramine hydrochloride. The generic form of this active ingredient is widely available in the market under various product names and manufacturers.


Q: What is the shelf life of Vivinox?

Official guidance requires the medicine to be stored at mathbfcontrolled room temperature and protected from heat and moisture. The actual shelf life is indicated by the mathbfexpiration date printed on the product packaging, according to manufacturer guidelines.


Q: Is Vivinox safe to use while traveling or flying?

The official label does mathbfnot provide specific safety guidance on using the medicine while traveling or flying. However, it does caution against engaging in activities requiring mental alertness, such as mathbfdriving, due to the drug's potential to cause mathbfdrowsiness and impaired coordination.


Q: What level of evidence supports the use of Vivinox for its main purpose?

Evidence supporting the short-term use for temporary sleeplessness is primarily derived from mathbfRandomized Controlled Trials (RCTs). These studies largely examined changes in a measurement called mathbfsleep onset latency (the time it takes to fall asleep) over short periods of use.


Q: Is Vivinox often used for conditions other than the main one listed?

While Vivinox is approved for temporary sleep difficulties, the active ingredient, mathbfdiphenhydramine, is also approved and used in other products for conditions like certain mathbfallergic symptoms, mathbfmotion sickness, and some symptoms of Parkinsonism.

How should Vivinox be stored and disposed of?

Official Storage and Disposal Requirements

Vivinox (Diphenhydramine hydrochloride) must be stored strictly according to regulatory mandates to ensure product stability and safety.

Storage Component Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Avoid excessive heat and protect from freezing.
Protection Keep containers tightly closed. The product must be protected from light and stored away from excess moisture.
Child Safety Mandatory instruction: Keep the medication out of the sight and reach of children.
Disposal Dispose of any unused or expired product in accordance with local requirements for pharmaceutical waste. Do not allow the product to enter the wastewater system or any body of water.

These conditions maintain the integrity of the coated tablet formulation and ensure safe handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vivinox found in:

A-Z Index: